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Abstract
Background: As the origin of a life-and-death signal detected from systemic arterial pressure, which sequentially
increases (pro-life) and decreases (pro-death) to reflect progressive dysfunction of central cardiovascular regulation
during the advancement towards brain stem death in critically ill patients, the rostral ventrolateral medulla (RVLM)
is a suitable neural substrate for mechanistic delineation of this fatal phenomenon. The present study assessed the
hypothesis that extracellular signal-regulated kinase 1/2 (ERK1/2), a member of the mitogen-activated protein
kinases (MAPKs) that is important for cell survival and is activated specifically by MAPK kinase 1/2 (MEK1/2), plays a
pro-life role in RVLM during brain stem death. We further delineated the participation of MAPK signal-interacting
kinase (MNK), a novel substrate of ERK in this process.
Methods: An experimental model of brain stem death that employed microinjection of the organophosphate
insecticide mevinphos (Mev; 10 nmol) bilaterally into RVLM of Sprague-Dawley rats was used, in conjunction with
cardiovascular, pharmacological and biochemical evaluations.
Results: Results from ELISA showed that whereas the total ERK1/2 was not affected, augmented phosphorylation
of ERK1/2 at Thr202 and Tyr204 in RVLM occurred preferentially during the pro-life phase of experimental brain
stem death. Furthermore, pretreatment by microinjection into the bilateral RVLM of a specific ERK2 inhibitor, ERK
activation inhibitor peptide II (1 nmol); a specific MEK1/2 inhibitor, U0126 (5 pmol); or a specific MNK1/2 inhibitor,
CGP57380 (5 pmol) exacerbated the hypotension and blunted the augmented life-and-death signals exhibited
during the pro-life phase. Those pretreatments also blocked the upregulated nitric oxide synthase I (NOS I)/protein
kinase G (PKG) signaling, the pro-life cascade that sustains central cardiovascular regulatory functions during
experimental brain stem death.
Conclusions: Our results demonstrated that activation of MEK1/2, ERK1/2 and MNK1/2 in RVLM plays a preferential
pro-life role by sustaining the central cardiovascular regulatory machinery during brain stem death via upregulation
of NOS I/PKG signaling cascade in RVLM.
Background
Although brain stem death is currently the legal defini-
tion of death in Taiwan and many countries [1,2], the
detailed cellular and molecular mechanisms underlying
this phenomenon of paramount medical importance are
still unclear. The invariable prognosis that asystole
occurs within hours or days after the diagnosis of brain
stem death [3] strongly suggests that permanent impair-
ment of the brain stem cardiovascular regulatory
machinery precedes death. Better understanding of the
mechanistic aspects of the dysfunction of central cardio-
vascular regulation during brain stem death should
therefore enrich the dearth of information currently
available on this fatal phenomenon.
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evaluation of brain stem death uses the organophosphate
poison mevinphos (3-(dimethoxyphosphinyloxyl)-2-bute-
noic acid methyl ester (Mev), a US Environmental Protec-
tion Agency Toxicity Category I pesticide, as the
experimental insult [4]. At the same time, as the origin of
a life-and-death signal [5] that reflects failure of the central
cardiovascular regulatory machinery during brain stem
death [6-8] and a brain stem site via which Mev acts to eli-
cit cardiovascular toxicity [9], the rostral ventrolateral
medulla (RVLM) is a suitable neural substrate for mechan-
istic evaluation of this fatal phenomenon [4]. Of interest is
that the waxing and waning of the life-and-death signal,
which mirrors the fluctuation of neuronal functionality in
RVLM, presents itself as the low-frequency (LF) compo-
nent in the systemic arterial pressure (SAP) spectrum of
intensive-care unit patients [6-8]. More importantly, the
distinct phases of augmentation followed by reduction of
the LF power exhibited during Mev intoxication [10-13]
can be designated the pro-life and pro-death phase of cen-
tral cardiovascular regulation in this model of brain stem
death [4]. Based on this model, our laboratory has pre-
viously demonstrated that nitric oxide (NO) generated by
NO synthase I (NOS I) in RVLM, followed by activation
of the soluble guanylyl cyclase/cyclic GMP/protein kinase
G (PKG) cascade, is responsible for the pro-life phase; per-
oxynitrite formed by a reaction between NOS II-derived
NO and superoxide anion underlies the pro-death phase
[10-13].
As death represents the end of existence for an indivi-
dual, we proposed previously [4] that multiple pro-life
and pro-death programs must be activated in RVLM
during the progression toward brain stem death. There-
fore, one meaningful direction in our search for the cel-
lular and molecular mechanisms of brain stem death is
to identify these regulatory programs. In this regard, the
extracellular signal-regulated kinases (ERKs) present
themselves as another reasonable candidate for the pro-
life program. As a member of the mitogen-activated
protein kinases (MAPKs), ERK1/2 pathway is activated
specifically by MAPK kinase 1/2 (MEK1/2), and is an
important signal for cell survival [14-19]. Sustained inhi-
bition of ERK expression leads to the induction of apop-
tosis in rat neuronal PC12 cells [15]. On the other hand,
ERK is strongly and persistently activated during cell
survival [16,17]. With particular relevance to this study,
ERK1/2 activation leads to NOS I induction in rat PC12
cells [18] and in rat aortic smooth muscle cells [19].
Based on our Mev intoxication model [4], the present
study evaluated the hypothesis that MEK1/2 and ERK1/
2 in RVLM play a pro-life role during brain stem death
by activating the NOS I/PKG cascade. We further deli-
neated the participation of MAPK signal-interacting
kinase (MNK), a novel substrate of ERK [20,21] in this
process. Our results demonstrated that activation of
MEK1/2, ERK1/2 and MNK1/2 in RVLM plays a prefer-
ential pro-life role by sustaining central cardiovascular
regulatory functions during brain stem death via upre-
gulation of the NOS I/PKG signaling cascade in RVLM.
Methods
Adult male Sprague-Dawley rats (285-345 g, n = 164)
purchased from the Experimental Animal Center of the
National Science Council, Taiwan, Republic of China
were used. All experimental procedures carried out in
this study have been approved by the Laboratory Animal
Committee of the Chang Gung Memorial Hospital-
Kaohsiung Medical Center, and were in compliance
with the guidelines for animal care set forth by this
Committee.
General preparation
Preparatory surgery was carried out under an induction
dose of pentobarbital sodium (50 mg/kg, i.p.), and
included cannulation of a femoral artery and a femoral
vein, together with tracheal intubation. During the
recording session, which routinely commenced 60 min
after the administration of pentobarbital sodium,
anesthesia was maintained by intravenous infusion of
propofol (Zeneca, Macclesfield, UK) at 20-25 mg/kg/h.
We have demonstrated previously [22] that this scheme
provided satisfactory anesthetic maintenance while pre-
serving the capacity of central cardiovascular regulation.
Body temperature of the animals was maintained at 37°
C with a heating pad, and rats were allowed to breathe
spontaneously with room air during the entire recording
session.
Animal model of brain stem death
The Mev intoxication model of brain stem death [4] was
used. Since Mev induces comparable cardiovascular
responses on given systemically or directly to RVLM [9],
we routinely microinjected Mev bilaterally into RVLM
to elicit site-specific effects [9-13]. SAP signals recorded
from the femoral artery were simultaneously subjected
to on-line power spectral analysis [9-13,23]. We were
particularly interested in the low-frequency (LF; 0.25-0.8
Hz) component in the SAP spectrum because its power
density mirrors the prevalence of baroreceptor reflex
(BRR)-mediated sympathetic neurogenic vasomotor dis-
charges that emanate from this brain stem site [23].
More importantly, our laboratory demonstrated pre-
viously [10-13] that the power density of this spectral
signal exhibits biphasic changes that reflect the pro-life
and pro-death phases seen during the progression
towards brain stem death in patients who succumbed to
organophosphate poisoning [8]. Heart rate (HR) was
derived instantaneously from SAP signals. Temporal
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satile SAP, mean SAP (MSAP) and HR were routinely
followed for 180 min after Mev administration in an on-
line and real-time manner.
Microinjection of test agents
Microinjection bilaterally of test agents into RVLM,
each at a volume of 50 nl, was carried out stereotaxi-
cally and sequentially [9-13] via a glass micropipette
connected to a 0.5-μl Hamilton (Reno, NV, USA)
microsyringe. The coordinates used were: 4.5-5 mm
posterior to lambda, 1.8-2.1 mm lateral to midline,
and 8.1-8.4 mm below the dorsal surface of cerebel-
lum. These coordinates were selected to cover the
ventrolateral medulla at which functionally identified
sympathetic premotor neurons reside [24]. Test
agents used included Mev (kindly provided by Huik-
wang Corporation, Tainan, Taiwan), a specific ERK2
inhibitor [25], ERK activation inhibitor peptide II
(Calbiochem, San Diego, CA, USA); a specific MEK1/
2 inhibitor [26,27], U0126 (Calbiochem); or a specific
MNK1/2 inhibitor [28,29], CGP57380 (Tocris, Ellis-
ville, MO, USA). All test agents used for pretreat-
ments were given 30 min before the administration of
Mev. The doses were adopted from previous reports
[25-29] that used those test agents for the same pur-
pose as in this study. Application of the same amount
of artificial cerebrospinal fluid (aCSF) controlled for
possible volume effect of microinjection of Mev, and
0.2% DMSO serving as the vehicle control for ERK
activation inhibitor peptide II, U0126 or CGP57380.
The composition of aCSF was (mM): NaCl 117,
NaHCO3 25, glucose 11, KCl 4.7, CaCl2 2.5, MgCl2
1.2 and NaH2PO4 1.2. To avoid the confounding
effects of drug interactions, each animal received only
one pharmacological treatment.
Collection of tissue samples from ventrolateral medulla
We routinely collected tissue samples for subsequent
biochemical evaluations [10-13] during the peak of the
pro-life and pro-death phase (Mev group), or 30 or 180
min after microinjection of aCSF or 0.2% DMSO into
RVLM (vehicle control group). Animals were killed with
an overdose of pentobarbital sodium and tissues from
both sides of the ventrolateral medulla, at the level of
RVLM (0.5-1.5 mm rostral to the obex), were collected
by micropunches made with a 1 mm (i.d.) stainless-steel
bore to cover the anatomical boundaries of RVLM.
Medullary tissues collected from anesthetized animals
but without treatment served as the sham-controls. The
concentration of total proteins extracted from those tis-
sue samples was determined by the BCA protein assay
(Pierce, Rockford, IL, USA).
ELISA for ERK or phosphorylated ERK
Cell lysate from ventrolateral medulla was subjected to
enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s protocol of a commercial kit (Cell
Signaling, Danvers, MA, USA) to detect the levels of
ERK1/2 or phosphorylated ERK1/2 at Thr202/Tyr204.
The final absorbance of reaction solution at 450 nm was
determined by spectrophotometry using an ELISA
microtiter plate reader (Anthros Labtec, Salzburg, Aus-
t r i a ) ,a n de x p r e s s e da sf o l dc h a n g e sa g a i n s ts h a m -
controls.
Western blot analysis
Western blot analysis [10-13,23] was carried out using
a rabbit polyclonal antiserum against NOS I, NOS II
(Santa Cruz, Santa Cruz, CA, USA) or PKG (Calbio-
chem); or a mouse monoclonal antiserum against
nitrotyrosine (Upstate, Lake Placid, NY, USA) or b-
actin (Chemicon, Temecula, CA, USA). This was fol-
lowed by incubation with horseradish peroxidase-con-
jugated donkey anti-rabbit IgG (Amersham
Biosciences, Little Chalfont, Bucks, UK) for NOS I,
NOS II or PKG, or sheep anti-mouse IgG (Amersham
Biosciences) for nitrotyrosine or b-actin. Specific anti-
body-antigen complex was detected by an enhanced
chemiluminescence Western blot detection system
(NEN, Boston, MA, USA). The amount of protein pro-
duct was quantified by the ImageMaster Video Docu-
mentation System (Amersham Pharmacia Biotech), and
w a se x p r e s s e da st h er a t i ot ob-actin protein.
Histology
In some animals that were not used for biochemical
analysis, the brain stem was removed at the end of the
physiological experiment and fixed in 30% sucrose in
10% formaldehyde-saline solution for at least 72 h. Fro-
zen 25-μm sections of the medulla oblongata stained
with neural red were used for histological verification of
the microinjection sites.
Statistical analysis
All values are expressed as mean ± SEM. The averaged
value of MSAP or HR calculated every 20 min after
administration of test agents or vehicle, the sum total of
power density for the LF component in the SAP spec-
trum over 20 min, or the protein expression level in
RVLM during each phase of experimental brain stem
death, were used for statistical analysis. One-way or
two-way ANOVA with repeated measures was used, as
appropriate, to assess group means. This was followed
by the Scheffé multiple-range test for post hoc assess-
ment of individual means. P < 0.05 was considered to
be statistically significant.
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Mev intoxication model of brain stem death
Figure 1 shows that co-microinjection bilaterally of Mev
(10 nmol) and vehicle into RVLM elicited a progressive
hypotension that became significant 100 min after appli-
cation, accompanied by indiscernible alterations in HR.
Concurrent changes in power density of the LF compo-
nent of SAP signals revealed two distinct phases [10-13].
The pro-life Phase I entailed a significantly augmented
LF power that endured 80-100 min to reflect sustained
brain stem cardiovascular regulatory functions. The pro-
death Phase II, which lasted the remainder of our 180-
min observation period, exhibited further and significant
reduction in the power density of this spectral compo-
nent to below baseline, which signifies failure of central
cardiovascular regulation that precedes brain stem death
[4].
Preferential activation of ERK1/2 in RVLM during the pro-
life phase
We first evaluated the fundamental premise that ERK1/2
in RVLM is activated during experimental brain stem
death. Quantification by ELISA revealed that the total
ERK1/2 in ventrolateral medulla was not affected by
microinjection of Mev into the bilateral RVLM (fig. 2).
Interestingly, phosphorylated ERK1/2 (pERK1/2) at
Thr202 and Tyr204 in RVLM was significantly and pre-
ferentially augmented during the pro-life phase (fig. 2),
of which returned to baseline during the pro-death
phase. The level of both ERK1/2 and pERK1/2 in ven-
trolateral medulla of vehicle groups was comparable to
sham-controls.
Activation of MEK1/2, ERK1/2 or MNK1/2 in RVLM
sustains central cardiovascular regulation associated with
experimental brain stem death
Based on the stipulation that the magnitude and dura-
tion of the LF component of SAP signals during experi-
mental brain stem death reflect the prevalence of the
life-and-death signal [4], we next employed pharmacolo-
gical blockade to evaluate whether a causal relationship
exists between activation of ERK1/2 in RVLM and cen-
tral cardiovascular regulation during brain stem death.
Pretreatment with microinjection into the bilateral
RVLM of ERK activation inhibitor peptide II (1 nmol),
which binds specifically to ERK2 to prevent its interac-
tion with MEK [25], exacerbated significantly the hypo-
tension and blunted the augmented power density of
the LF component of SAP signals during the pro-life
phase (fig. 1), without affecting HR. Similar results were
obtained on local application bilaterally into RVLM of
U 0 1 2 6( 5p m o l ) ,as p e c i f i ci n h i b i t o ro fM E K 1a n d
MEK2 [26,27] (fig. 1). Those pretreatments also
significantly shortened the pro-life phase to 25-35 min
by shifting the prevailing phase of the 180-min observa-
tion period toward the pro-death phase (fig. 1). Intrigu-
ingly, comparable results were also obtained on
pretreatment with microinjection bilaterally into RVLM
of CGP57380 (5 pmol), a specific cell-permeable
MNK1/2 inhibitor [28,29] (fig. 1); although a dose of 1
p m o lw a si n e f f e c t i v ea g a i n s tt h ec a r d i o v a s c u l a r
responses during the pro-life phase (maximal MSAP:
112.5 ± 5.2 versus 113.0 ± 5.8 mmHg; maximal HR:
356.8 ± 20.1 versus 354.6 ± 16.6 bpm; maximal LF
power: 73.6 ± 6.7 versus 75.2 ± 7.5 mmHg
2 when com-
pared to 0.2% DMSO pretreatment; mean ± SEM, n = 4
animals). On the other hand, ERK activation inhibitor
peptide II, U0126 or CGP57380 did not significantly
affect the hypotension and decrease in LF power already
exhibited during the pro-death phase. Furthermore, pre-
treatment with vehicles exerted minimal effects on the
phasic cardiovascular responses.
Activation of MEK1/2 or ERK1/2 underlies the
augmentation of NOS I or PKG in RVLM during the pro-
life phase
We previously demonstrated [10-13] that NOS I/PKG
signaling in RVLM is responsible for sustaining central
cardiovascular regulation during the pro-life phase in
our Mev intoxication modelo fb r a i ns t e md e a t h .I ti s
therefore conceivable that MEK1/2 or ERK1/2 in RVLM
may confer its pro-life actions via the NOS I/PKG cas-
cade. As reported previously [10-13], Western blot ana-
lysis revealed a significant augmentation of NOS I or
PKG expression in ventrolateral medulla during the pro-
life phase, followed by a return to baseline during the
pro-death phase (fig. 3). Pharmacological blockade was
again used to ascertain that these temporally correlated
biochemical changes are causally linked to MEK1/2 or
ERK1/2 activation in RVLM during experimental brain
stem death. Pretreating animals by microinjection into
the bilateral RVLM of ERK activation inhibitor peptide
II (1 nmol) or U0126 (5 pmol) significantly blunted the
augmented NOS I or PKG protein expression at ventro-
lateral medulla during the pro-life phase (fig. 3). On the
other hand, the protein levels of NOS I and PKG during
the pro-death phase were not affected by these
pretreatments.
Activation of MEK1/2 or ERK1/2 is not responsible for the
augmentation of NOS II or peroxynitrite in RVLM during
the pro-death phase
We also demonstrated in our previous studies [10-13]
that a progressive augmentation of NOS II and nitrotyr-
osine (an experimental index for peroxynitrite) expres-
sion in RVLM underlies the failure of central
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Page 4 of 9Figure 1 Activation of MEK1/2, ERK1/2 or MNK1/2 in RVLM sustained central cardiovascular regulation associated with experimental
brain stem death. Temporal changes in mean systemic arterial pressure (MSAP), hear rate (HR) or power density of low-frequency (LF)
component of SAP signals in rats that received pretreatment by microinjection bilaterally into RVLM of vehicle (Veh; aCSF or 0.2% DMSO), ERK
activation inhibitor peptide II (Peptide II; ERK2 inhibitor), U0126 (MEK1/2 inhibitor) or CGP57380 (MNK1/2 inhibitor), 30 min before local
application (at arrow) of aCSF or Mev (10 nmol) to the bilateral RVLM. Values are mean ± SEM, n = 5-7 animals per experimental group. *P <
0.05 versus Veh+aCSF group, and
+P < 0.05 versus Veh+Mev group at corresponding time-points in the Scheffé multiple-range test.
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brain stem death. As such, MEK1/2 or ERK1/2 activa-
tion in RVLM may also lead to an antagonism of this
augmentation. However, pretreatment with ERK activa-
tion inhibitor peptide II (1 nmol) or U0126 (5 pmol),
similar to the vehicle controls, exerted no influence
against the increase of NOS II and nitrotyrosine protein
expression in ventrolateral medulla during both phases
of experimental brain stem death (fig. 4).
Activation of MNK1/2 leads to upregulation of NOS I or
PKG in RVLM during the pro-life phase
Our final series of experiments investigated whether
activation of MNK1/2 is upstream to the augmented
NOS I or PKG expression in RVLM during the pro-life
phase. Western blot analysis again revealed that micro-
injection bilaterally into RVLM of an effective dose of
CGP57380 (5 pmol) significantly blunted the elevated
NOS I or PKG protein level at ventrolateral medulla
during the pro-life phase of experimental brain stem
death (fig. 3), without affecting the increase of NOS II
or nitrotyrosine protein expression (fig. 4).
Discussion
Based on a clinically relevant experimental model [4],
the present study provided novel demonstrations that
MEK1/2 or ERK1/2 activation in RVLM sustains central
cardiovascular regulation during the progression towards
brain stem death. We further showed that mechanisti-
cally, this pro-life role was executed via upregulation of
the pro-life NOS I/PKG signaling cascade by MNK1/2.
It is generally contended that of the three MAPKs
characterized in mammals, ERK1/2 plays a crucial role
in survival responses [30-33]. On the other hand, Jun N-
terminus kinase (JNK) and p38 MAPK primarily med-
iate inflammatory response [34,35] and promote cell
death [36-38]. In rats that received transient middle cer-
ebral artery occlusion, pERK is strongly expressed at the
ischemic penumbra in cerebral cortex and is essentially
involved in cell survival [33]. The MEK/ERK survival
pathway mediates neuroprotection of striatal neurons
[32] or hippocampal CA1/CA3 neurons [31] against glu-
tamatergic neuronal cell death. It also protects sympa-
thetic neurons against apoptosis induced by the
antimitotic nucleoside cytosine arabinoside [30]. The
Figure 2 Activation of ERK1/2 in RVLM during the pro-life
phase of experimental brain stem death. Changes in total ERK or
phosphorylated ERK at Thr202 and Tyr204 in folds relative to sham-
control (SC), detected in ventrolateral medulla during the pro-life
phase I (MI) or pro-death phase II (MII) of experimental brain stem
death or during comparable time points after treatment with aCSF
(AI or AII). Values are presented as mean ± SEM of triplicate analyses
on tissue samples pooled from 5-7 animals in each experimental
group. *P < 0.05 versus corresponding aCSF group (AI or AII) in the
Scheffé multiple-range analysis.
Figure 3 Activation of MEK1/2, ERK1/2 or MNK1/2 leads to
phasic upregulation of NOS I/PKG cascade in RVLM during
experimental brain stem death. Illustrative gels or summary of
fold changes against aCSF controls in ratio of nitric oxide synthase I
(NOS I) or protein kinase G (PKG) relative to b-actin protein
detected in ventrolateral medulla of rats that received ERK
activation inhibitor peptide II, U0126 or CGP57380 into bilateral
RVLM, 30 min before induction of experimental brain stem death.
Values are mean ± SEM of triplicate analyses on samples pooled
from 5-7 animals per experimental group. *P < 0.05 versus aCSF
group and
+P < 0.05 versus Mev group in the Scheffé multiple-
range test.
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for MEK1/2 or ERK1/2 at RVLM in the form of a pro-
life role during experimental brain stem death.
We previously demonstrated a pro-life role for NOS I/
PKG cascade at RVLM in experimental brain stem
death [10-13]. The present study further revealed that
this pro-life signaling cascade is downstream to activa-
tion of MEK/ERK in RVLM. This demonstration is
echoed by the observation [19] that gene transfer or
gene knockdown of MEK increases or decreases NOS I
expression in cultured rat aortic smooth muscle cells.
Moreover, the MEK/ERK pathway, but not JNK or p38
MAPK, is required for NOS I mRNA or protein expres-
sion and activity in PC12 cells [18]. There are two possi-
ble, though not necessarily mutually exclusive,
mechanisms for MEK/ERK to elicit NOS I induction.
One possibility is for ERK1/2 to transcriptionally upre-
gulate NOS I. The promoter region of NOS I gene con-
tains putative cis-elements of binding sites for cAMP
response element (CREB), C/EBP and c-Myc [39,40],
which are candidates for ERK nuclear targeting in the
mediation of gene transcription. Another possibility is
for ERK to exert posttranslational modification by phos-
phorylation of NOS I protein. ERK1/2 is tightly bound
to its physiologically relevant substrates, such as MNKs
and p90RSK1 for subsequent physiological responses.
Whereas p90RSK1 is a well-known substrate for ERK1/
2, MNK1 and MNK2 are novel serine/threonine protein
kinases that could be phosphorylated by ERK1/2 [20].
MNK1 activation is inhibited by MEK inhibitor
PD98059 [20,21], suggesting that it is an important reg-
ulator for MNK activation. It follows that MNK1/2 may
enhance phosphorylation of NOS I on activation by
MEK/ERK. Whether the implied augmentation of NOS
I or PKG expression in RVLM by MNK1/2 observed
during experimental brain stem death in the present
study entails transcriptional upregulation remains to be
investigated.
Our results also showed that the pro-life role of MEK,
E R Ka n dM N Ki nR V L Md u r i n ge x p e r i m e n t a lb r a i n
stem death is manifested by sustaining central cardio-
vascular regulation. In this regard, it is of interest to
note that these cellular signals may be linked to angio-
tensin II (Ang II), a well-known peptide that is crucial
to the elevation of SAP in RVLM. Activation of the
ERK/CREB/c-fos cascade mediates the long-term
pressor effect of Ang II in RVLM [26]. MEK and ERK1/
2 also participate in Ang II-induced vascular smooth
muscle cell contraction [41]. Furthermore, MNK med-
iates Ang II-induced protein synthesis in vascular
smooth muscle cells [29]. Whether Ang II in RVLM
plays a pro-life role during brain stem death via activa-
tion of the MEK/ERK/MNK cascade, however, awaits
documentation.
Conclusion
In conclusion, the present study revealed that the MEK/
ERK/MNK cascade in RVLM plays a pro-life role during
experimental brain stem death by sustaining the central
cardiovascular regulatory machinery via NOS I/PKG
signaling.
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